Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSe Trial

被引：5
|
作者：
Mazieres, J. [1 ]
Montane, L. [2 ]
Barlesi, F. [3 ]
Coudert, B. [4 ]
Souquet, P. J. [5 ]
Otto, J. [6 ]
Gervais, R. [7 ]
Moro-Sibilot, D. [8 ]
Monnet, I. [9 ]
Brain, E. [10 ]
Huillard, O. [11 ]
Quere, G. [12 ]
Debieuvre, D. [13 ]
Fabre, E. [14 ]
Jaffro, M. [1 ]
Collot, S. [1 ]
Ferretti, G. [8 ]
Tiffon, C. [15 ]
Oukhatar, C. Mahier-Ait [16 ]
Blay, J. [2 ]
机构：
[1] Hop Larrey, CHU Toulouse, Toulouse, France
[2] Ctr Leon Berard, Lyon, France
[3] Aix Marseille Univ, AP HM, Aix En Provence, France
[4] Ctr Georges Francois Leclerc, Dijon, France
[5] Hop Lyon Sud, Ctr Hosp, Pierre Benite, France
[6] Ctr Antoine Lacassagne, Nice, France
[7] Ctr Francois Baclesse, Caen, France
[8] Hop Michallon, CHU Grenoble, Grenoble, France
[9] Ctr Hosp Intercommunal Creteil, Creteil, France
[10] Hop Rene Huguenin, Inst Curie, St Cloud, France
[11] Hop Univ Paris Ctr, Hop Cochin, Paris, France
[12] Chru Brest Hop Morvan, Brest, France
[13] Ctr Hosp Mulhouse, Mulhouse, France
[14] Hop Univ Paris Ouest, Hop Europeen Georges Pompidou, Paris, France
[15] lnst Natl Canc, Boulogne, France
[16] Unicanc, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
NSCLC; Vemurafenib; BRAF mutation;
D O I：
10.1016/j.jtho.2018.08.302
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA12.05
引用
收藏
页码：S348 / S349
页数：2
相关论文
共 50 条
  • [1] Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSe trial
    Mazieres, J.
    Montane, L.
    Barlesi, F.
    Quantin, X.
    Tredaniel, J.
    Le Treut, J.
    Avrillon, V.
    Lavole, A.
    Westeel, V.
    Piocelle, F. Orsini
    Pichon, E.
    Thiberville, L.
    Borel, C.
    Renault, P. A.
    Jaffro, M.
    Collot, S.
    Ferretti, G.
    Legrand, F.
    Oukhatar, C. Mahier Ait
    Blay, J. Y.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [2] Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSe basket trial
    Tomasini, P.
    Mazieres, J.
    Cropet, C.
    Troussard, X. G.
    Malka, D.
    Ray-Coquard, I. L.
    Leboulleux, S.
    Flechon, A.
    Arnulf, B.
    Cancel, M.
    Bieche, I.
    Collot, S.
    Taieb, S.
    Garcia, G.
    Mandache, A-M.
    Colignon, N.
    Gavrel, M.
    Jimenez, M.
    Hoog-Labouret, N.
    Blay, J-Y.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S470 - S471
  • [3] Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: first results of the ACSE trial
    Blay, J-Y.
    Mazieres, J.
    Perol, D.
    Barlesi, F.
    Moro-Sibilot, D.
    Quere, G.
    Tredaniel, J.
    Troussard, X.
    Leboulleux, S.
    Malka, D.
    Flechon, A.
    Linassier, C.
    Ray-Coquard, I. L.
    Arnulf, B.
    Bieche, I.
    Ferretti, G.
    Nowak, F.
    Jimenez, M.
    Hoog-Labouret, N.
    Buzyn, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [4] Melanoma Effectiveness of Vemurafenib on BRAF V600 Mutations
    Voos, Dunja
    [J]. AKTUELLE DERMATOLOGIE, 2014, 40 (11) : 434 - 434
  • [5] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
    Hyman, David M.
    Puzanov, Igor
    Subbiah, Vivek
    Faris, Jason E.
    Chau, Ian
    Blay, Jean-Yves
    Wolf, Juergen
    Raje, Noopur S.
    Diamond, Eli L.
    Hollebecque, Antoine
    Gervais, Radj
    Elena Elez-Fernandez, Maria
    Italiano, Antoine
    Hofheinz, Ralf-Dieter
    Hidalgo, Manuel
    Chan, Emily
    Schuler, Martin
    Lasserre, Susan Frances
    Makrutzki, Martina
    Sirzen, Florin
    Veronese, Maria Luisa
    Tabernero, Josep
    Baselga, Jose
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08): : 726 - 736
  • [6] BRAF V600 and Non-V600 Mutations in Chinese Lung Cancer
    Gao, Y.
    Chang, R.
    Huan, J.
    Xiao, X.
    Liu, Y.
    Zhou, Y.
    Li, L.
    Cheng, Y.
    Zhang, C.
    Dai, P.
    Guan, Y.
    Yi, X.
    Xia, X.
    Yang, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S911 - S911
  • [7] Treatment of patients with advanced melanoma harboring the BRAF V600 mutation
    Polowinczak-Przybylek, Joanna
    Potemski, Piotr
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 48 - 52
  • [8] Beyond BRAF V600: Characterizing the genomic landscape of non-BRAF V600 mutations and BRAF fusions in 121,221 in adult patients with cancer
    Coleman, N.
    Gouda, M. A.
    Roszik, J.
    Subbiah, V.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S589 - S589
  • [9] BRAF V600 and non-V600 mutations across distinct tumor types.
    Xie, Qichao
    Huan, Jiaojiao
    Zhao, Jun
    Chen, Yu
    Gao, Jie
    Liang, Naixin
    Zeng, Yu
    Liu, Lianke
    Xu, Chunwei
    Chen, Chen
    Guan, Yan-Fang
    Yang, Ling
    Xia, Xuefeng
    Yi, Xin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] VEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION
    Haanen, J. B. A. G.
    Scholtens, A.
    Geukes, M.
    van Thienen, H.
    van Tinteren, H.
    [J]. ANNALS OF ONCOLOGY, 2014, 25
12345